David Apelian's most recent trade in Eiger BioPharmaceuticals Inc was a trade of 750,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 3, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Eiger BioPharmaceuticals Inc | David Apelian | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 750,000 | 750,000 | - | - | Stock Option (Right to Buy) | |
| Eiger BioPharmaceuticals Inc | David Apelian | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Eiger BioPharmaceuticals Inc | David Apelian | Director | Sale of securities on an exchange or to another person at price $ 9.81 per share. | 16 Aug 2022 | 5,000 | 11,000 (0%) | 0% | 9.8 | 49,031 | Common Stock |
| Eiger BioPharmaceuticals Inc | David Apelian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Eiger BioPharmaceuticals Inc | David Apelian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 5,000 | 10,000 (0%) | 0% | 0 | Common Stock |